Table 2

TERT in situ hybridisation results

Sample numberDiagnosis TERT promoter* TERT expression (qRT-PCR)*In situ hybridisation
TERT1 TERT2
1wiFTCMutatedYesFocalNeg
2wiFTCMutatedYesFocalFocal
3wiFTCMutatedYesNegNeg
4wiFTCMutatedYesFocalFocal
5wiFTCMutatedYesFocalFocal
6miFTCMutatedYesFocalFocal
7wiFTCMutatedYesNegNeg
8FT-UMPMutatedYesNegFocal
9FT-UMPMutatedYesNegFocal
10HCCMutatedYesFocalFocal
11miFTCWildtypeNoneNegNeg
12miFTCWildtypeNoneNegNeg
13eaiFTCWildtypeNoneNegNeg
14miFTCWildtypeNoneNegNeg
15wiFTCWildtypeNoneNegNeg
16wiFTCWildtypeNoneNegNeg
17miFTCWildtypeNoneNegNeg
18wiFTCWildtypeNoneNegNeg
19wiFTCWildtypeNoneNegNeg
20miFTCWildtypeNoneNegNeg
21wiFTCWildtypeNoneNegNeg
22wiFTCWildtypeNoneNegNeg
23wiFTCWildtypeNoneNegNeg
24wiFTCWildtypeNoneNegNeg
25wiFTCWildtypeNoneNegNeg
26eaiFTCWildtypeNoneNegNeg
  • *Retrieved from Paulsson et al. 9

  • eaiFTC, encapsulated angioinvasive follicular thyroid carcinoma; FT-UMP, follicular thyroid tumour of uncertain malignant potential; HCC, Hürthle cell carcinoma; miFTC, minimally invasive follicular thyroid carcinoma; Neg, negative; qRT-PCR, quantitative real-time PCR; wiFTC, widely invasive follicular thyroid carcinoma.